Cell line · CVCL_1177
DMS 53
Cancer cell line, Homo sapiens. Lung small cell carcinoma. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. DMS 53. Cell lines, record CVCL_1177. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1177
On this page
Cell line
As Cellosaurus gives it.
- Name
- DMS 53
- Accession
- CVCL_1177
- RRID
- RRID:CVCL_1177
- Synonyms
- DMS-53, DMS53, Darmouth Medical School 53
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 54Y
- Category
- Cancer cell line
- Diseases
- Lung small cell carcinoma (NCIt C4917); Small cell lung cancer (ORDO Orphanet_70573)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for TMEM175 (UniProt ID: Q9BSA9) for use in western blot, immunoprecipitation, and immunofluorescence. | F1000Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer. | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sympathetic Neurons Promote Small Cell Lung Cancer through the β2-Adrenergic Receptor. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for CSNK1A1 (UniProt ID: P48729) for use in western blot, immunoprecipitation, and immunofluorescence. | F1000Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for ADNP (UniProt ID: Q9H2P0) for use in western blot, immunoprecipitation, and immunofluorescence. | F1000Res | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 34
See all 34 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | DMS 53 HTT KO | CVCL_D6U0 |
Source Cell lines
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-2062 | ATCC | |
| AddexBio | C0016027/4988 | Cellosaurus | |
| ECACC | 95062823 | ECACC |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1177
GET https://conductscience.org/api/cell-lines/v1/CVCL_1177/papers?page=2